New pill could tame stubborn hives
NCT ID NCT07005713
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got the real drug. The main goals were to check safety and how the drug moves through the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-16673 (an oral drug)
What this could lead to
If successful, this could lead to a new oral treatment option for people with chronic hives that are not controlled by antihistamines.
What could go wrong
This is a very early Phase 1b trial with only 34 participants, focused on safety and dosing. It is too small and early to know if the drug will effectively reduce hives or be safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chengdu Second Peoples Hospital
Chengdu, Sichuan, 610021, China
-
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
Hangzhou First Peoples Hospital
Hangzhou, Zhejiang, 310006, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 630014, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China